Human IL-31 Biotinylated Antibody Summary
Ser24-Thr164
Accession # NP_001014358
Applications
Human IL-31 Sandwich Immunoassay
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Reconstitution Calculator
Preparation and Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: IL-31
Human Interleukin-31 (IL-31) is a 24 kDa, short-chain member of the alpha -helical family of cytokines. The human IL-31 cDNA encodes a 164 amino acid (aa) precursor that contains a 23 aa signal peptide and a 141 aa mature protein (1, 2). The mature region shows four alpha -helices which would be expected to show a typical up-up-down-down topology. Human and mouse IL-31 share 24% aa sequence identity in the mature region (1). IL-31 is mainly associated with activated T cells and preferentially expressed by Th2 rather than Th1 cells. IL-31 signals via a heterodimeric receptor complex composed of a 120 kDa, gp130-related molecule termed IL-31 RA (also GPL and GLM-R) and the 180 kDa oncostatin M receptor (OSM R beta ) (2 - 6). In the complex, IL-31 directly binds to GPL, not OSM R (2, 3). IL-31 signaling has been shown to involve the Jak/STAT pathway, the PI3 kinase/AKT cascade, and the MAP kinase pathway (2 - 5). Although multiple isoforms of IL-31 RA are known, only a form that contains the entire length of the cytoplasmic domain is signaling-capable (2, 3). The IL-31 receptor is constitutively expressed by keratinocytes and upregulated by IFN-gamma on monocytes (1). Studies using transgenic mice indicate that IL-31 may contribute to the pruritis (itching) associated with nonatopic dermatitis (1, 7).
- Dillon, S.R. et al. (2004) Nat. Immunol. 5:752.
- Diveu, C. et al. (2004) Eur. Cytokine Netw. 15:291.
- Dreuw, A. et al. (2004) J. Biol. Chem. 279:36112.
- Diveu, C. et al. (2003) J. Biol. Chem. 278:49850.
- Ghilardi, N. et al. (2002) J. Biol. Chem 277:16831.
- Mosley, B. et al. (1996) J. Biol. Chem. 271:32635.
- Takaoka, A. et al. (2005) Eur. J. Pharmacol. 516:180.
Product Datasheets
Citation for Human IL-31 Biotinylated Antibody
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
1 Citation: Showing 1 - 1
-
Improved pruritus correlates with lower levels of IL-31 in CTCL patients under different therapeutic modalities
Authors: Filiberto Cedeno-Laurent, Elisha M. Singer, Maria Wysocka, Bernice M. Benoit, Carmela C. Vittorio, Ellen J. Kim et al.
Clinical Immunology
FAQs
No product specific FAQs exist for this product, however you may
View all Antibody FAQsReviews for Human IL-31 Biotinylated Antibody
There are currently no reviews for this product. Be the first to review Human IL-31 Biotinylated Antibody and earn rewards!
Have you used Human IL-31 Biotinylated Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image